Beijing Med-Pharm
Overview    
BMP Sunstone is a Delaware Corporation with Chinese subsidiaries. We are able to offer an end-to-end solution to western pharmaceutical companies interested in selling their products into the Chinese marketplace.

Services we offer include:

  • Pre-market entry analysis
  • Clinical trial management
  • Pre-registration and registration of pharmaceuticals for sale in the People's Republic of China
  • Market research
  • Pharmaceutical marketing to physicians, hospitals, and other healthcare providers
  • Pharmaceutical distribution to hospitals

In December 2004, Beijing Med-Pharm signed an agreement to purchase Beijing Wanwei Pharmaceutical Corporation, Ltd., a pharmaceutical distributor covering the bulk of Beijing's hospitals.

This was a historic event, the first-ever purchase of a Chinese pharmaceutical distribution company by a foreign entity, permitted only after a December 2004 change in Chinese law.

By adding this distributor to our already-existing sales and marketing services, BMP Sunstone hopes to offer an unparalleled opportunity to reach China, the world's fastest-growing market. And our veteran pharmaceutical management staff makes it simple for you to do so.

BMP Sunstone serves as your entry point for pharmaceutical distribution into China.

Contact us for more information on how we can best serve you.

BMP Sunstone CEO David Gao (left) signs an agreement with the Beijing Wan Hui Pharmaceutical Group, represented by Chairman Wang Zhaoyi (right), to purchase the Beijing Wanwei Pharmaceutical Corporation, Ltd.